Androgen binding in prostatic carcinoma by histochemistry: update 1985.
Fluorescent androgen ligands were employed to study putative androgen-binding (AB) sites in a number of men with prostatic adenocarcinoma. Results were compared with biochemical androgen receptor determinations in over 150 patients with agreement in 86% (p less than 0.001). AB by histochemistry correlated significantly with the outcome of hormonal manipulation (p less than 0.001) but not with response to radiation therapy (p = 0.55) or to 125I implantation (p = 0.54). There was a degree of positive interaction between histochemically and biochemically determined AB sites which produced a significant improvement in assay specificity (p less than 0.05). These findings indicate that the best method for prediction of hormone response in prostate cancer is provided by a combination of assay techniques.
D000230:Adenocarcinoma / Q000032:analysis* / Q000188:drug therapy; D001665:Binding Sites; D005453:Fluorescence; D006651:Histocytochemistry; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000032:analysis* / Q000188:drug therapy; D011485:Protein Binding; D011944:Receptors, Androgen / Q000032:analysis*
D006728:Hormones; D011944:Receptors, Androgen